Subscribing to the so-called Netflix model for purchasing hepatitis C treatments is projected to lower patient costs by approximately 85 percent in Australia, where the government is working its way through a five-year deal in which several drug makers were paid a lump sum of $766 million for the medicines, according to an analysis in the New England Journal of Medicine.

Under emerging Netflix models — which vary — states or countries agree to pay a fixed amount of money to receive unlimited treatments of a drug for a patient population.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Interesting approach to cost savings and public health. It sounds like a good deal for both sides. The fly in the ointment, however, might be reinfection. I’m assuming that most of the cases of Hepatitis C in Australia, as in the US, are from IV drug use.

    Unless all those infected can be treated quickly and/or there is a stop to IV drug use, there will possibly be a reservoir of continuous re-infected individuals who will need to be retreated. This will also raise the specter of resistance developing to this drugs

    Not a prediction; just a cautionary note. It will be interesting to see how it works out, particularly, if this approach does lead to the eradication or near eradication of Hepatitis C.

  • Nice article, however, I think it failed to emphasize the biggest reason the cost was so low. That was good old Capitalism and real competition where Abbvie and others mentioned were able to make their own Hep C drug so much cheaper then Gileads > $120,000 3 month cure. That is how competition should work in an open market. This affordability factor is why one could actually predict the end of Hepatitis C in developed country. Hat’s off to the Researchers and to real competition.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy